Bio-Bridge-Science Inc. CEO Dr. Liang Qiao Featured in CEOcast Interview

Bio-Bridge-Science Inc. (OTCBB:BGES) announced that CEO
Dr. Liang Qiao is featured in an interview with CEOcast. The topics of
discussion include the company's unique technology platform and its
promising new HIV vaccine. Dr. Qiao also elaborates upon Bio-Bridge
Science's plans and prospects for the upcoming year. The interview is
available through CEOcast and can now be heard at www.ceocast.com in
the latest interviews section.

   About Bio-Bridge Science:

   Bio-Bridge Science is a biotechnology firm focused on the
development of vaccines with broad therapeutic and preventive
applications. Through its wholly owned subsidiary in Beijing,
Bio-Bridge is developing a promising new HIV Vaccine, that is expected
to enter clinical trials this year in China. The vaccine, based on
exclusive technology co-developed by CEO Liang Qiao, an associate
professor at Loyola University Chicago's Strich School of Medicine,
targets infection in mucosal tissues, the first type of tissue
attacked by HIV.
   The Chinese government, mindful of the rapid expansion of AIDS in
China has, through the "Green Mile Policy" acted to expedite the
approval of domestically produced HIV Vaccines and has dramatically
increased its spending on AIDS-related research. In accordance with
this policy, Bio-Bridge expects to bring its therapeutic HIV Vaccine
to market as early as 2008, far in advance of many other HIV Vaccines
currently in development. Bio-Bridge is currently constructing a new
$3 million state-of-the-art GMP research and manufacturing facility in
Beijing, which is expected to be completed by mid-year.